首页> Molecular oncology> Development and initial clinical testing of a multiplexed circulating tumor cell assay in patients with clear cell renal cell carcinoma.

Development and initial clinical testing of a multiplexed circulating tumor cell assay in patients with clear cell renal cell carcinoma.

导出 OA

翻译打印收藏纠错

第一作者： Rory M,Bade

第一单位： Carbone Cancer Center, University of Wisconsin-Madison, WI, USA.

作者： Rory M,Bade ^[1] ; Jennifer L,Schehr ^[1] ; Hamid,Emamekhoo ^[2] ; Benjamin K,Gibbs ^[1] ; Tamara S,Rodems ^[1] ; Matthew C,Mannino ^[1] ; Joshua A,Desotelle ^[2] ; Erika,Heninger ^[1] ; Charlotte N,Stahlfeld ^[1] ; Jamie M,Sperger ^[3] ; Anupama,Singh ^[1] ; Serena K,Wolfe ^[1] ; David J,Niles ^[4] ; Waddah,Arafat ^[3] ; John A,Steinharter ^[5] ; E,Jason Abel ^[3] ; David J,Beebe ^[4] ; Xiao X,Wei ^[5] ; Rana R,McKay ^[6] ; Toni K,Choueri ^[5] ; Joshua M,Lang ^[3]

作者单位： Carbone Cancer Center, University of Wisconsin-Madison, WI, USA. ^[1] Department of Medicine, University of Wisconsin-Madison, WI, USA. ^[2] Carbone Cancer Center, University of Wisconsin-Madison, WI, USA.;Department of Medicine, University of Wisconsin-Madison, WI, USA. ^[3] Department of Biomedical Engineering, University of Wisconsin-Madison, WI, USA. ^[4] Lank Center for Genitourinary Oncology, Dana-Farber Cancer Institute, Harvard University, Boston, MA, USA. ^[5] Lank Center for Genitourinary Oncology, Dana-Farber Cancer Institute, Harvard University, Boston, MA, USA.;Moores Cancer Center, University of California San Diego, La Jolla, CA, USA. ^[6]

关键词 biomarkers circulating tumor cells clear cell renal cell carcinoma exclusion-based sample preparation pharmacodynamic prognostic